Biocon Names insider Shreehas Tambe as MD & CEO
Biocon announced that Siddharth Mittal, Managing Director and Chief Executive Officer, will be resigning from his current role on March 31 and will assume a new leadership position within the organization. In his place, Shreehas Pradeep Tambe has been chosen as his successor.
The board has endorsed the selection of Tambe, who currently serves as the CEO and MD of Biocon Biologics, to join as an additional director starting from April 1, 2026. Tambe will also assume the role of CEO and MD for a period of five years, contingent upon the approval of shareholders.
Also Read: Kiran Mani Joins ChatGPT-maker OpenAI to Lead APAC Operations
Upon his resignation, Mittal will no longer hold the position of a major managerial figure in the company. The company has mentioned that his considerations for the new position within the Biocon Group signify an internal shift in leadership.
Tambe's appointment was made in accordance with the recommendation of the Nomination and Remuneration Committee and adheres to regulatory standards, the company announced.
Furthermore, it was noted that he has not been prohibited from serving as a director by any directive from the Securities and Exchange Board of India or any other governing body. The company further disclosed that interim Chief Financial Officer Mukesh Kamath will be resigning from his position, effective at the end of business hours on March 31, 2026, as he moves into a new role within the Biocon Group.
Also Read: CM Naidu Urges Officials to Reduce Cost of Power Purchase
The board has granted approval for the selection of Kedar Narayan Upadhye, who presently serves as the Chief Financial Officer of Biocon Biologics, to assume the role of Chief Financial Officer of the company starting on April 1, 2026.
Moreover, Biocon Biologics has disclosed its plans to introduce three novel biosimilars at the upcoming 2026 J.P. Morgan Healthcare Conference scheduled to take place from January 12-16, 2026 in San Francisco.
These new biosimilars, which have not yet been assigned names, are intended for pembrolizumab (in relation to MSD’s Keytruda®), nivolumab (in relation to BMS’ Opdivo®) and trastuzumab/hyaluronidase (in relation to Roche’s Herceptin® SC, known in the US as Herceptin Hylecta™).
Bioéticos announced the release of the first pembrolizumab biosimilar in Paraguay in August 2025, which was named Pembrolizumab Bioéticos. In November of the same year, Biocad's Pembroria™ (pembrolizumab) received approval in Vietnam. Several other companies, such as Samsung Bioepis, Amgen, mAbxience, Sandoz, Celltrion, Bio-Thera, and BioNTech, are currently conducting clinical trials for pembrolizumab biosimilars.
Also Read: Nitin Gadkari Unveils Raajmarg Infra Investment Trust
Alvotech and Dr. Reddy's have formed a global partnership and license agreement to collaborate on the development, manufacturing, and commercialization of a biosimilar to Keytruda®.
In December 2025, Formycon made announcements about agreements with MS Pharma for the commercialization of their pembrolizumab biosimilar, FYB206, in the MENA region, as well as agreements with Zydus Lifesciences for distribution in the United States and Canada.
Several nivolumab biosimilars are currently in various stages of clinical trials, such as Sandoz’s JPB898 in phase I, Amgen’s ABP 206 in phase III, Xbrane/Intas’ Xdivane™ in phase I/III, Boan Biotech’s BA1104 in phase III, and Reliance Life Sciences’ R-TPR-067 in phase I/II. Furthermore, Shanghai Henlius revealed in December 2025 that the FDA had granted approval for an Investigational New Drug (IND) application for a phase I trial of HLX18 (nivolumab).